MX2020002196A - Moduladores receptores de tipo a de ácido gammaaminobutírico novedosos para trastornos del humor. - Google Patents

Moduladores receptores de tipo a de ácido gammaaminobutírico novedosos para trastornos del humor.

Info

Publication number
MX2020002196A
MX2020002196A MX2020002196A MX2020002196A MX2020002196A MX 2020002196 A MX2020002196 A MX 2020002196A MX 2020002196 A MX2020002196 A MX 2020002196A MX 2020002196 A MX2020002196 A MX 2020002196A MX 2020002196 A MX2020002196 A MX 2020002196A
Authority
MX
Mexico
Prior art keywords
acid type
aminobutyric acid
receptor modulators
mood disorders
gamma aminobutyric
Prior art date
Application number
MX2020002196A
Other languages
English (en)
Inventor
Scott Thompson
Dyke Adam Van
Craig Thomas
Patrick Morris
Original Assignee
Univ Maryland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Maryland filed Critical Univ Maryland
Publication of MX2020002196A publication Critical patent/MX2020002196A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a moduladores alostéricos negativos selectivos de la subunidad alfa5 novedosos de receptores GABAA que han sido deuterados para mejorar sus propiedades medicinales al prolongar sus semividas, haciéndolos útiles como tratamientos farmacéuticos de rápida acción para los trastornos relacionados con la depresión.
MX2020002196A 2017-08-28 2018-08-28 Moduladores receptores de tipo a de ácido gammaaminobutírico novedosos para trastornos del humor. MX2020002196A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762550826P 2017-08-28 2017-08-28
PCT/US2018/048339 WO2019046300A1 (en) 2017-08-28 2018-08-28 NOVEL MODULATORS OF GAMMA-AMINOBUTYRIC ACID RECEPTOR TYPE A FOR MOOD DISORDERS

Publications (1)

Publication Number Publication Date
MX2020002196A true MX2020002196A (es) 2020-09-28

Family

ID=65525999

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020002196A MX2020002196A (es) 2017-08-28 2018-08-28 Moduladores receptores de tipo a de ácido gammaaminobutírico novedosos para trastornos del humor.

Country Status (11)

Country Link
US (2) US11459320B2 (es)
EP (1) EP3675845A4 (es)
JP (2) JP7403050B2 (es)
KR (1) KR20200044906A (es)
CN (1) CN111201016A (es)
AU (1) AU2018323443A1 (es)
BR (1) BR112020004116A2 (es)
CA (1) CA3074110A1 (es)
EA (1) EA202090521A1 (es)
MX (1) MX2020002196A (es)
WO (1) WO2019046300A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201016A (zh) 2017-08-28 2020-05-26 马里兰大学巴尔的摩分校 针对情绪疾患的新型γ氨基丁酸A型受体调节剂
CA3216863A1 (en) 2021-05-05 2022-11-10 University College Cardiff Consultants Limited Heteroaryl compounds useful in the treatment of cognitive disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5301557B2 (ja) 2007-12-04 2013-09-25 エフ．ホフマン−ラ ロシュ アーゲー イソオキサゾロ−ピリジン誘導体
US8222246B2 (en) * 2009-04-02 2012-07-17 Hoffmann-La Roche Inc. Substituted isoxazoles
US8604062B2 (en) * 2011-10-20 2013-12-10 Hoffman-La Roche Inc. Process for the preparation of isoxazolyl-methoxy nicotinic acids
US8785435B2 (en) 2011-10-20 2014-07-22 Hoffmann-La Roche Inc. Solid forms
EP3125902B1 (en) 2014-03-31 2020-09-16 University of Maryland, Baltimore Use of negative modulators of gaba receptors containing alpha5 subunits as fast acting antidepressants
WO2016192680A1 (en) 2015-06-03 2016-12-08 Triastek, Inc. Dosage forms and use thereof
CA2968836A1 (en) * 2016-06-13 2017-12-13 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
CN111201016A (zh) 2017-08-28 2020-05-26 马里兰大学巴尔的摩分校 针对情绪疾患的新型γ氨基丁酸A型受体调节剂

Also Published As

Publication number Publication date
US20200199119A1 (en) 2020-06-25
JP2023133571A (ja) 2023-09-22
JP7403050B2 (ja) 2023-12-22
US11897875B2 (en) 2024-02-13
EP3675845A1 (en) 2020-07-08
KR20200044906A (ko) 2020-04-29
CN111201016A (zh) 2020-05-26
JP2021500309A (ja) 2021-01-07
BR112020004116A2 (pt) 2020-09-01
US20220396572A1 (en) 2022-12-15
WO2019046300A9 (en) 2020-10-15
EA202090521A1 (ru) 2020-06-10
CA3074110A1 (en) 2019-03-07
US11459320B2 (en) 2022-10-04
EP3675845A4 (en) 2021-05-05
WO2019046300A1 (en) 2019-03-07
AU2018323443A1 (en) 2020-03-12

Similar Documents

Publication Publication Date Title
MX2017015133A (es) Procesos para producir brivaracetam.
TN2016000143A1 (en) Compositions and methods for modulating farnesoid x receptors.
NZ737399A (en) Ccr2 modulators
EA201792515A1 (ru) ЗАМЕЩЕННЫЕ СОЕДИНЕНИЯ ТЕТРАГИДРОХИНОЛИНОНА В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕТИНОИДНЫХ ОРФАНОВЫХ РЕЦЕПТОРОВ ГАММА (RORγ)
AU2018247351B2 (en) Methods and compositions for treatment of demyelinating diseases
MX2015005858A (es) Moduladores del receptor acoplado a proteina g (gpr40) de dihidropirazol.
MX358499B (es) Moduladores de dihidropirazol del receptor acoplado a la proteína g (gpr40).
MX2015005720A (es) Moduladores de dihidropirazol de receptor acoplado a la proteina g (gpr40).
EA201700504A1 (ru) 5-ароматическое алкинилзамещенное бензомидное соединение и способ его получения, фармацевтическая композиция и их применение
EA201692037A1 (ru) Пирролидиновые модуляторы gpr40 для лечения расстройств, таких как диабет
MX2015011932A (es) Moduladores de gpr120 de acido biciclo[2.2.2].
MX2021010783A (es) Formulaciones de anticuerpo anti-il-36r.
MX2020006235A (es) Nuevos derivados de benzamida como moduladores de ppar-gamma.
PH12017501280B1 (en) Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators
MX2020005336A (es) Analogos de d-serina deuterados y usos de los mismos.
EA201792594A1 (ru) Положительные аллостерические модуляторы мусаринового рецептора м1
MX2015011375A (es) Moduladores del receptor acoplado a proteina-g 120 (gpr120) de acido biciclo-[2.2.1].
MX2020002196A (es) Moduladores receptores de tipo a de ácido gammaaminobutírico novedosos para trastornos del humor.
MX2017009292A (es) Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3.
EA201892235A1 (ru) Гранулированная композиция для перорального применения
PH12017501876A1 (en) Pyridopyrimidones and their use as nmda receptor modulators
EA202090995A1 (ru) Полициклические амиды в качестве положительных аллостерических модуляторов мускариновых рецепторов м1
EA201791657A1 (ru) Модуляторы аденозиновых рецепторов a
ZA202109194B (en) A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator
AU2019268209A1 (en) Compounds for the treatment of seizures and other central nervous system disorders and conditions